Webinars and Presentations

Webinars & Presentations

Applications

Virus-like Particles
Cell Based Assays
Cell Therapy
CRISPR/Gene Editing
Gene Editing
Protein Production

Cell Types

Cancer Cell Lines
CHO
Dendritic Cells
HEK293
HSPCs
Insect Cell Lines (S2/Sf9/Sf21)
ion channels
iPSCs
NK Cells
NPCs/NSCs
PBMCs
T Cells

CRISPR/Gene Editing

Gene Editing

Primary Cells

TCR/CAR T

CAR T

Seminar: Non-viral Cell Engineering Advantages and Applications with Stanford University, Touchlight and MaxCyte

Key case studies are presented by Dr. Hyatt Want at Stanford University (Crystal Mackall & Steve Feldman Labs), Dr. Elena Stoyanova at Touchlight Genetics, and Dr. Marianna Romito at MaxCyte. Each presenter shares data on how to increase engineering efficiency in primary and stem cells, all while maintaining high cell viability and recovery for applications in gene editing and autologous/allogeneic cell therapy.

Cell Therapy

CAR T

T Cells

Seminar: University of Pennsylvania – High Efficiency Cell Engineering

The High Efficiency Cell Engineering Seminar was hosted at the University of Pennsylvania on Friday, October 27, 2023, with our special guest, Nils Wellhausen, who is co-mentored by Drs. Carl June and Saar Gill, recently published a novel therapeutic strategy for the treatment of most blood cancers. This presentation showcased the development of fratricide-resistant, base-edited CD45-targeting CAR T cells and CD45 epitope-edited hematopoietic stem cells. This approach paves the way forward for a universal blood cancer immune therapy.

Cell Therapy

CRISPR/Gene Editing

Gene Therapy

TCR/CAR T

CHO

iPSCs

T Cells

Seminar: Non-viral Cell Engineering – Catamaran, CCRM and MaxCyte

Register to delve into the future of cellular engineering by viewing the on demand seminar on Non-viral Cell Engineering from Catamaran, CCRM and MaxCyte. Our special guest, Catamaran Bio, will showcase their innovative, transposon-based approach to CAR-NK cell engineering and demonstrate how MaxCyte and CCRM scientists helped enable their clinical development and advancement.

Cell Therapy

Protein Production

Vaccines

NK Cells

T Cells

Webinar: CHOp your protein production timelines

Learn how to drive your biologics development forward by leveraging MaxCyte^® Flow Electroporation^® technology. This flexible, scalable technology enables alternative strategies for the rapid development of high-yielding stable cell lines and can deliver gram-scale transient protein production within two weeks. Hosted with Labroots on September 12, 2023.

Cell Therapy

CRISPR/Gene Editing

Gene Editing

Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Watch the video to learn how choosing a clinically validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing.

Cell Based Assays

Cell Therapy

CRISPR/Gene Editing

iPSCs

T Cells

Seminar: High Efficiency Cell Engineering at Stanford University – Featured Guest Speaker: Dr. Hyatt Balke-Want

Hosted at Stanford University on July 6, 2023. Access this on demand seminar and learn more about how academic & industry labs utilize MaxCyte’s platforms to efficiently engineer primary cells, stem cells, and cell lines all while maintaining high cell viabilities & recovery for applications such as CRISPR, cell-based assays, protein production, viral production and more.

Cell Therapy

CRISPR/Gene Editing

Gene Editing

CAR T

Presentation: Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

Non-viral site directed CAR integration can be accomplished using CRISPR/Cas9 and double-stranded DNA (dsDNA) via homology-directed repair (HDR), however yields with this approach have been limiting for clinical application. We discuss here a targeted but HDR-independent approach for the manufacture of CAR-T cell therapies – Presented during JSGE, June 2023

Cell Based Assays

Cell Therapy

CRISPR/Gene Editing

iPSCs

T Cells

Presentation: Diversity of Therapeutic Approaches

Global Challenges, Opportunities, and Views from the United States, Europe, and Asia – Presented during ASGCT 2023

CRISPR/Gene Editing

Gene Editing

Primary Cells

TCR/CAR T

CAR T

Webinar: Memory-rich CAR-T cell engineering by piggyBac transposon system for solid malignancies

Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The quality of CAR-T cell products, including T-cell memory signatures and exhaustion-related markers, is critical for the function of CAR-T cell therapies. We have developed novel piggyBac transposon (PB) -based CAR-T cells with favorable characteristics and durable antitumor efficacy against solid malignancies. Webinar broadcasted on Labroots March 30, 2023.